635698-56-5

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 2,4-DICHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE is used as a key intermediate in the synthesis of various drugs. Its unique molecular structure and properties make it an important compound in the field of medicinal chemistry, contributing to the development of new pharmaceuticals with potential therapeutic benefits.
Used in Medicinal Chemistry Research:
TERT-BUTYL 2,4-DICHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE is used as a subject of study in medicinal chemistry research. Its potential medicinal properties are being explored to understand its therapeutic applications and to develop new drugs with improved efficacy and safety profiles.

InChI:InChI=1/C12H15Cl2N3O2/c1-12(2,3)19-11(18)17-5-4-8-7(6-17)9(13)16-10(14)15-8/h4-6H2,1-3H3

Upstream product

• 41276-30-6 C₉H₁₄O₃NC₆H₅ 

Downstream Products

• 635698-58-7 tert-butyl 2-chloro-4-(2-chloro-4-fluorobenzylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carboxylate 
• 1207358-19-7 C₂₄H₂₈N₈O₂ 
• 1207358-03-9 C₂₀H₂₆N₆O₂ 
• 1207358-49-3 C₂₆H₃₆N₆O₄ 
• 1207358-51-7 C₂₁H₂₈N₆O₂ 
• 1542711-17-0 N-tert-butyl 4-(benzylamino)-2-chloro-7,8-dihydropyrido-[4,3-d]pyrimidine-6(5H)-carboxylate 
• 1542711-20-5 C₂₈H₃₁N₅O₂ 
• 1542704-38-0 N-benzyl-2-(2-methyl-1H-indol-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 1542705-58-7 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[4,3-d]-pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide 

Relevant academic research and scientific papers

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)

The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin-proteasome system (UPS) mediated protein degradation, endoplasmic reticulum-associated degradation (ERAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-5083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell death. In tumor bearing mice, oral administration of 71 causes rapid accumulation of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to sustained antitumor activity in in vivo xenograft models of both solid and hematological tumors. 71 has been taken into phase 1 clinical trials in patients with multiple myeloma and solid tumors.